We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.56%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
126
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$582K 0.08%
11,701
+572
+5% +$29.6K
AKBA icon
127
CALL
Akebia Therapeutics
AKBA
$354M
$575K 0.08%
+800,000
New +$1.71M
ICPT
128
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$572K 0.08%
35,149
+584
+2% +$9.15K
KOD icon
129
PUT
Kodiak Sciences
KOD
$2.6B
$565K 0.07%
+73,100
New +$2.85M
AVTX icon
130
Avalo Therapeutics
AVTX
$965M
$554K 0.07%
265
+15
+6% +$37.7K
DMAC icon
131
DiaMedica Therapeutics
DMAC
$342M
$553K 0.07%
221,252
+12,170
+6% +$34.5K
MBIO icon
132
Mustang Bio
MBIO
$4.32M
$551K 0.07%
729
+54
+8% +$44.4K
OKUR
133
OnKure Therapeutics
OKUR
$154M
$546K 0.07%
18,560
+1,060
+6% +$59.3K
VTVT icon
134
vTv Therapeutics
VTVT
$127M
$536K 0.07%
18,575
+1,075
+6% +$32.2K
CRBP icon
135
Corbus Pharmaceuticals
CRBP
$166M
$530K 0.07%
33,254
+1,636
+5% +$21.7K
KOD icon
136
Kodiak Sciences
KOD
$2.6B
$526K 0.07%
+68,100
New +$2.66M
OTIC
137
DELISTED
Otonomy, Inc.
OTIC
$525K 0.07%
218,538
+10,232
+5% +$21.7K
RETA
138
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$502K 0.07%
15,300
-184,700
-92% -$5.48M
ASMB icon
139
Assembly Biosciences
ASMB
$498M
$468K 0.06%
18,923
+1,018
+6% +$21.9K
BDTX icon
140
Black Diamond Therapeutics
BDTX
$96.8M
$441K 0.06%
159,390
+8,906
+6% +$32.5K
AGTC
141
DELISTED
Applied Genetic Technologies Corporation
AGTC
$440K 0.06%
412,293
+21,899
+6% +$39.8K
IRD
142
Opus Genetics
IRD
$306M
$401K 0.05%
124,021
+5,958
+5% +$20.4K
HYFT
143
MindWalk Holdings
HYFT
$60.6M
$399K 0.05%
77,650
+3,768
+5% +$19.4K
NRSN icon
144
NeuroSense Therapeutics
NRSN
$16.8M
$397K 0.05%
+100,000
New +$238K
RGLS
145
DELISTED
Regulus Therapeutics
RGLS
$384K 0.05%
128,913
+6,071
+5% +$15.8K
GRI
146
GRI Bio
GRI
$2.44M
– –
0
– –
ZLAB icon
147
Zai Lab
ZLAB
$2.06B
$376K 0.05%
+81,843
New +$3.96M
FATE icon
148
Fate Therapeutics
FATE
$286M
$374K 0.05%
9,640
+602
+7% +$23.3K
KA
149
DELISTED
Kineta, Inc. Common Stock
KA
$355K 0.05%
33,755
+1,075
+3% +$13.2K
CYTO
150
DELISTED
Altamira Therapeutics Ltd
CYTO
$351K 0.05%
800
+38
+5% +$18.4K
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.